pro, version 2023 (treeage software)
90
Structured Review
treeage software
pro, version 2023
Pro, Version 2023, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/origin+software+version+2021/pro+version+2021/pmc11570631-228-7-7
Average 90 stars, based on 1 article reviews
Pro, Version 2023, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/origin+software+version+2021/pro+version+2021/pmc11570631-228-7-7
Average 90 stars, based on 1 article reviews
pro, version 2023 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Cost-Effectiveness of Addressing Retinopathy of Prematurity in Rwanda. Article Snippet: We used Article Title: Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model Article Snippet: We also used SPSS v. 23.0 (SPSS, Chicago, IL, USA) for the descriptive and inferential statistics and used Article Title: Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis Article Snippet: This model included a 3-week cycle period and was used to simulate the patient lifetime, and model construction was performed with Article Title: Cost utility analysis of antibiotics compared with operative treatment in uncomplicated acute appendicitis. Article Snippet: Data were analyzed in STATA version 16, and all simulations were performed by Article Title: Cost utility analysis of antibiotics compared with operative treatment in uncomplicated acute appendicitis Article Snippet: Data were analyzed in STATA version 16, and all simulations were performed by Article Title: Ivonescimab plus chemotherapy in advanced or metastatic non‑squamous non‑small cell lung cancer with EGFR variant in China: a cost-effectiveness analysis Article Snippet: The simulated total costs (efficacy) of patients in the ivonescimab and chemotherapy groups were integrated in the construction of a Markov model simulating the natural course of patients in the two groups from the perspective of Chinese society by using the Article Title: Supply, Demand, and a Growing US Kidney Transplant Waiting List. Article Snippet: Modeling and analysis were completed using Software:Article Title: Cost-effectiveness analysis of mHealth applications for depression in Germany using a Markov cohort simulation Article Snippet: .. We built our model in the software |